A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.
Journal article, 2010
Multiple Outcomes of Raloxifene Evaluation (MORE), a placebo controlled phase III study of raloxifene in postmenopausal osteoporosis, showed that both doses tested (60 mg and 120 mg daily) reduced the risk of vertebral fracture. There was no significant effect on non-vertebral fracture.
epidemiology
Spinal Fractures
Placebos
Humans
Incidence
Proportional Hazards Models
therapeutic use
Algorithms
therapeutic use
epidemiology
Osteoporotic Fractures
80 and over
drug therapy
Risk Factors
Middle Aged
Treatment Outcome
Female
Adult
Aged
drug therapy
Raloxifene
Aged
Bone Density Conservation Agents
Author
John A Kanis
Helena Johansson
Anders Odén
Eugene V McCloskey
Bone
1873-2763 (ISSN)
Vol. 47 4 729-35Subject Categories
Endocrinology and Diabetes
DOI
10.1016/j.bone.2010.06.009
PubMed
20601292